Indegene Limited · NSE:INDGN
Indegene — Q2 FY2027 Earnings Presentation
23 slides from Indegene's earnings presentation, October 2026
Slide 1: Investor Presentation Q2'FY27
Investor Presentation Q2’FY27
Slide 2: Disclaimer
Disclaimer This presentation may include opinions and assumptions about future performance which could be considered as forward-looking statements. Forward-looking statements intrinsically cover several risks and uncertainties, which may lead to a material difference between actual results and the s
Slide 3: Quarterly Performance Q2'FY27
Quarterly Performance Q2’FY27 Acceleration in growth with stable margin REVENUE FROM OPERATIONS REVENUE PER EMPLOYEE INR 11,223 M USD 117.5 M $79.6 K ▲ 39.5% ▲ 5.6% ▲ 27.5% ▲ 4.4% ▲ 15.5% ▲ 3.3% YoY in INR QoQ in INR YoY in USD QoQ in USD YoY QoQ EBITDA PAT DSO ₹ 1,873 M ₹ 1,123 M 69 Days 16.7% of R
Slide 4: Continued momentum in Revenue Growth in INR and USD
Continued momentum in Revenue Growth in INR and USD INR 21,854 M +39.6% +27.0% H1’FY27 Revenue from Operations H1’FY27 Revenue Growth YoY in INR H1’FY27 Revenue Growth YoY in USD REVENUE (INR M) REVENUE (USD M) ▲ 39.5% YoY ▲ 27.5% YoY 11,223 117.5 10,631 109.7 112.5 10,034 106.1 9,421 92.2 8,042 Q2’
Slide 5: Both Engines firing together leading to Growth acceleration
Both Engines firing together leading to Growth acceleration Deeper penetration of top accounts and a wider, taller client pyramid are compounding revenue growth Deeper Engagement with Large Customers Broader Targeting — Wider, Taller Pyramid ❑ Top-10 clients up 13.5% QoQ ❑ $1M+ clients more than dou
Slide 6: Q2 Margins held firm, drivers in place for Expansion
Q2 Margins held firm, drivers in place for Expansion EBITDA MARGIN · Q2 FY27 16.7% PBT MARGIN · Q2 FY27 13.1% Held near Q1 despite the wage hike Absorbed a near-term yield dip EBITDA margin walk (%) PBT margin bridge (%) ETR steady: 23.8% (Q1: 23.9%) Annual wage increase now fully in the base; lever
Slide 7: Q2'FY27 Business Highlights
Q2’FY27 Business Highlights Expanding customer base | Improving revenue productivity | Strengthening global delivery Customer Growth & Productivity Global Delivery Excellence ACTIVE CLIENT RELATIONSHIPS⁽¹⁾ 107 HEALTHCARE DELIVERY EXPERTISE 28.8% Clients served Share of delivery team with domain skil
Slide 8: Management Commentary on Q2 FY'27 results
Management Commentary on Q2 FY’27 results Extending our strong start to FY27, Q2 revenue grew 5.6% Despite the annual wage increase that takes effect in our second sequentially in INR, our fifth successive quarter above 5%. Growth quarter, EBITDA margin remained stable at 16.7%, a marked was broad-b
Slide 9: Indegene is a new category – not a better version of an old one
Indegene is a new category – not a better version of an old one Embedded Revenue Partner E • Operate in clients' revenue-generating engine: Commercial & Med teams behind launches, brands & growth $79.6K REVENUE / EMPLOYEE • Sit on growth-side budgets, not IT cost budgets; less exposed to cost-cuttin
Slide 10: One Year of BioPharm: Delivering on the Thesis
One Year of BioPharm: Delivering on the Thesis Integrated ahead of plan | Savings reinvested in growth | A richer data estate, embedded in how we win SUCCESSFULLY INTEGRATED DATA ASSETS Savings Realized, Reinvested in Growth A Richer HCP Data Estate ~$1.5M 3x 1 Month At acquisition TODAY Annual cost
Slide 11: Recognized for Innovation and Excellence (2026-27)
Recognized for Innovation and Excellence (2026-27) Industry Excellence People/ Culture Excellence Indegene earns two Platinum Hermes Creative Awards 2026 across the Won by CultHealth, an Live/Hybrid Event Indegene company, for (Indegene Digital Summitt GTFO—created with 2025) and BCPP’s Campaign for
Slide 12: Indegene Digital Summit 2026
Indegene Digital Summit 2026 Philadelphia 22 Sep 2026 12 120+ 19 Venue Date Keynotes and panels Senior pharma attendees Pharma Speakers Keynote speakers David Shulkin Amol Punjabi Ninth Secretary Chief Product Officer U.S. Department of OpenEvidence Veterans Affairs Agam Upadhyay Corinne Le Goff Chi
Slide 13: Financial Highlights
Financial Highlights es ) imdegene
Slide 14: Q2'FY27: Consolidated Financials
Q2’FY27: Consolidated Financials Amount in ₹ Millions Particulars Q2 FY27 Q1 FY27 Q2 FY26 QoQ % YoY % Revenue from Operations 11,223 10,631 8,042 5.6% 39.5% Employee Benefit Expenses 6,817 6,591 5,158 3.4% 32.2% Other Expenses 2,549 2,298 1,478 10.9% 72.5% Other Income 17 52 12 -67.3% 37.1% EBITDA 1
Slide 15: Q2'FY27: Stable Business mix
Q2’FY27: Stable Business mix Revenue from Service offering ($ M) Revenue by Customer Industry (%)* Revenue by Customer Geography (%) 3.0% 2.0% 92.2 112.5 117.5 3.2% 3.6% 3.7% 4.2% 2.2% 74.5% 22.9% 68.5% 70.6% 71.3% 0.4% 27.9% 25.7% 24.5% 91.8% Q2'FY26 Q1'FY27 Q2'FY27 Enterprise Medical Solutions Bio
Slide 16: Annexure
Annexure i | imdegene’
Slide 17: We operate at the intersection of healthcare and technology
We operate at the intersection of healthcare and technology Tech-Led Healthcare Delivery and Expertise Digital Capabilities Healthcare market understanding In-depth domain knowledge Digital-first approach GenAI based tools and platform Navigating regulatory landscape Medical content know-how Drive t
Slide 18: Our large addressable market is underpinned by growing outsourcing and rapid digital adoption
Our large addressable market is underpinned by growing outsourcing and rapid digital adoption Large Market Opportunity Outsourcing and Tech Lifesciences at Inflection We Offer Solutions Expanding our TAM Point Across Life Sciences Life Sciences Operations Spend Across End Markets Verticals ($B) Pate
Slide 19: Full-Stack Capabilities & GenAI Platforms Driving Multi-Quarter Operating Model Transformation
Full-Stack Capabilities & GenAI Platforms Driving Multi-Quarter Operating Model Transformation • Scaled an Agentic AOR pilot into a full-scale engagement, Full-Stack, Diverse Capabilities with Large cutting content creation timelines from months to days Complex Skillsets Creative Pharma • Began with
Slide 20: Dual-Pronged GenAI Strategy: Accelerate value for clients today while building for tomorrow
Dual-Pronged GenAI Strategy: Accelerate value for clients today while building for tomorrow Existing Products New Products New Areas/Capabilities Extend capabilities of existing products to capture more value Unlock value from new avenues that have opened up due to EXTEND via cross-sell/up-sell (New
Slide 21: Thank You!
Thank You! www.indegene.com
Slide 22: Fact Sheet
Fact Sheet Consolidated Financial Data - Second Quarter, Fiscal 2027 Operational & Financial Metrics Key performance indicators (in INR Mn) Quarter ended Growth SI. Particulars Sep 30, June 30, Sep 30, No. YoY QoQ 2026 2026 2025 1. Active clients(1)(No.) 107 105 72 40.8% 1.9% 2. Revenue from operati
Slide 23: Fact Sheet
Fact Sheet Consolidated Financial Data - Second Quarter, Fiscal 2027 Revenue by customer industry (in %) Quarter ended (contribution) Growth Particulars Sep 30, June 30, Sep 30, YoY QoQ 2026 2026 2025 Biopharma 91.8 91.6 92.0 39.2% 5.7% Medical Devices 3.0 3.1 3.5 22.7% 2.3% Emerging Biotech 3.2 3.3